BioCentury
ARTICLE | Finance

Clever chemistry

Why seed investor Merck Ventures returned for Inthera's series A round

June 3, 2017 12:53 AM UTC

Three of Inthera Bioscience AG's seed investors returned for a CHF10.5 million ($10.8 million) series A round to bring the company's lead protein-protein interaction inhibitor to the clinic.

Merck Ventures led the round, which closed on May 31. Aglaia BioMedical Ventures, Novo Seeds and an undisclosed private investor also participated...

BCIQ Company Profiles

Inthera Bioscience AG